Lund University Hospital

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: Private

Established: 1768-01-01

Employees: -

Market Cap: -

Website: http://www.skane.se/sus

Clinical Trials

Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0

Phase 1

Completed

Conditions: Locally Advanced Cancer in the Anal Region

Interventions: Drug: Cetuximab
Drug: Mitomycin C
Drug: 5-Fluoruracil
Radiation: Radiotherapy

First Posted Date: 2012-06-18

Last Posted Date: 2020-02-28

Lead Sponsor: Lund University Hospital

Target Recruit Count: 21

Registration Number: NCT01621217

Locations: 🇸🇪
Accademic Hospital, Dept. of Oncology, Uppsala, Sweden
🇳🇴
University Hospital, Dept. of Oncology, Oslo, Norway
🇸🇪
Skåne University Hospital, Dept. of Oncology, Lund, Sweden

A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors

Phase 2

Completed

Conditions: Liver Metastases
Neuroendocrine Tumors

Interventions: Drug: 177Lu-DOTA-TATE

First Posted Date: 2011-10-20

Last Posted Date: 2019-09-30

Lead Sponsor: Lund University Hospital

Target Recruit Count: 60

Registration Number: NCT01456078

Locations: 🇸🇪
Department of Oncology, Lund University Hospital, Lund, Sweden
🇸🇪
Sahlgrenska University Hospital, Department of Oncology, Göteborg, Sweden

Enumeration and Molecular Characterization of Circulating Tumour Cells in Women With Metastatic Breast Cancer

Completed

Conditions: Metastatic Breast Cancer

First Posted Date: 2011-03-25

Last Posted Date: 2020-05-22

Lead Sponsor: Lund University Hospital

Target Recruit Count: 150

Registration Number: NCT01322893

Locations: 🇸🇪
Lund University Hospital, Lund, Sweden

Pneumococcal Vaccination of Otitis-prone Children

Not Applicable

Completed

Conditions: Recurrent Acute Otitis Media

Interventions: Biological: Prevenar

First Posted Date: 2010-12-20

Last Posted Date: 2010-12-20

Lead Sponsor: Lund University Hospital

Target Recruit Count: 109

Registration Number: NCT01263210

Locations: 🇸🇪
ENT Department, Lund University Hospital, Lund, Sweden

Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Drug: bevacizumab, erlotinib
Drug: bevacizumab
Drug: low dose capecitabine

First Posted Date: 2010-10-28

Last Posted Date: 2015-04-13

Lead Sponsor: Lund University Hospital

Target Recruit Count: 233

Registration Number: NCT01229813

Locations: 🇸🇪
University Hospital, Linköping, Sweden
🇸🇪
County Hospital, Kalmar, Sweden
🇸🇪
County Hospital Ryhov, Jönköping, Sweden

and more 6 locations

Early Insulin Treatment in Patients With Latent Autoimmune Diabetes

Phase 4

Completed

Conditions: Diabetes, Autoimmune
Diabetes Mellitus, Adult-Onset

Interventions: Drug: Insulin

First Posted Date: 2010-04-23

Last Posted Date: 2010-04-23

Lead Sponsor: Lund University Hospital

Target Recruit Count: 42

Registration Number: NCT01109927

Endocrine Dysfunction and Quality of Life After Subarachnoid Hemorrhage

Completed

Conditions: Endocrine Dysfunction
Cerebral Infarctions
Quality of Life

First Posted Date: 2010-04-12

Last Posted Date: 2012-09-07

Lead Sponsor: Lund University Hospital

Target Recruit Count: 50

Registration Number: NCT01101711

Locations: 🇸🇪
Department of Neurosurgery, Lund, Sweden

Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia

Phase 2

Completed

Conditions: Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia

Interventions: Drug: Clofarabine for remission induction
Drug: Etoposide for remission induction
Drug: Cyclophosphamide for remission induction
Drug: Clofarabine in conditioning before transplantation
Drug: Thiotepa in conditioning before transplantation
Drug: Melfalan in conditioning before transplantation
Procedure: Haploidentical transplantation of T-cell depleted graft
Procedure: Donor lymphocyte infusion

First Posted Date: 2009-12-04

Last Posted Date: 2021-02-21

Lead Sponsor: Lund University Hospital

Target Recruit Count: 7

Registration Number: NCT01025778

Locations: 🇸🇪
Lund University Hospital, Lund, Sweden

Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer

Phase 1

Completed

Conditions: Stomach Cancer
Gall Bladder Cancer
Bile Ductus Cancer
Pancreas Cancer
Colorectal Cancer

Interventions: Other: oxaliplatin, capecitabine, radiotherapy

First Posted Date: 2009-11-19

Last Posted Date: 2011-10-17

Lead Sponsor: Lund University Hospital

Target Recruit Count: 106

Registration Number: NCT01016639

Locations: 🇸🇪
Karolinska University Hospital, Stockholm, Sweden
🇸🇪
Akademiska Sjukhuset, Uppsala, Sweden
🇸🇪
Centralsjukhuset, Dept of Oncology, Karlstad, Sweden

and more 2 locations

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Phase 1

Completed

Conditions: Mantle Cell Lymphoma

Interventions: Drug: lenalidomide, bendamustine, rituximab

First Posted Date: 2009-08-21

Last Posted Date: 2018-03-12

Lead Sponsor: Lund University Hospital

Target Recruit Count: 51

Registration Number: NCT00963534

Locations: 🇳🇴
University Hospital of Stavanger, Department of Haematology and Oncology, Stavanger, Norway
🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
🇳🇴
Ulleval University Hospital, Department of Oncology, Oslo, Norway

and more 14 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy